Acces to hypomethylating agents in elderly Acute Myeloid Leukemia in French care network

30%. Fifty pwecent lived in in an urban and 50% in a rural rural area. Neoplasias included: Lung cancer 30%, Breast cancer 40%, gastric cancer, bladder and ovarian cancer in the same proportion (10%). Performance status ECOG was 0-1 for 60% of patients and 2 for other 40%. The comorbidities included arterial hypertension, ischemic cardiac disease, peripheral vascular disease, diabetes mellitus type 2, gallstones, urinary stones. The metabolic panel and LDH were normal in all patients. Forty percent of patients received both second and third line chemotherapy. Number of cycles of chemotherapy ranged between 6 and 24, PFS ranged between 3 to 9 month. The cytostatics used were: gemcitabine, paclitaxel, carboplatin, erlotinib, capecitabine, oxaliplatin, 5 fluorouracil cyclophosfphamide, methotrexate.There were on episodes of grade 4-5 toxicity and toxicity never dictated e interruption of chemotherapy or hospitalization. Grade 1-3 toxicities included: anemia, asthenia, weight loss. All patients hadfamily caregivers. Conclusion: In the highly selected population of senior patients referred to our cancer center the effectiveness and complications of chemotherapy were not different from those observed in younger adults. Our pilot study demonstrates that chronologic age is not a contraindication to cytotoxic chemotherapy. Our results also show a worrisome trend. As only 20 od the 150 patients examinedwere 70 and older one must conclude that the majority of older cancer patients do not receive antineoplastic chemotherapy and are undertreated.